Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASF-1057
- Development stage
- Phase 3
- Lead developer
- Astion Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ASF-1057 is a non-steroidal anti-inflammatory topical cream developed by Astion Pharma A/S for the treatment of seborrhoeic dermatitis. The active ingredient is monooctanoin, a small molecule that acts as an immunomodulator by modulating neurogenic inflammation. ASF-1057 has completed Phase II clinical studies in France and the United Kingdom, demonstrating potential as a topical treatment for inflammatory skin conditions. It is designed to provide a therapeutic alternative to traditional steroidal treatments by targeting neuro-inflammatory pathways.
- Other names
- monooctanoinglycerol monooctanoateglyceryl monocaprylate
Beyond the preview
Go deeper on ASF-1057.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASF-1057.